Literature DB >> 11903369

Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma.

J J Homer1, J Greenman, N D Stafford.   

Abstract

This pilot study investigated the potential use of three circulating angiogenesis-related cytokines, basic fibroblast growth factor (bFGF), angiogenin (ANG) and endostatin, as tumour markers and prognostic factors in patients with head and neck squamous cell carcinoma (HNSCC). A total of 30 patients with HNSCC treated with curative intent and 15 healthy controls were studied. Serum (bFGF and ANG) and plasma (endostatin) was assayed by enzyme-linked immunoabsorbance assay (ELISA). None of the cytokines was raised in HNSCC patients when compared with controls. Serum bFGF was not associated with any clinico-pathological or outcome parameters, although there was a trend towards higher levels in more advanced and aggressive tumours. Lower serum angiogenin (sANG) levels were associated with loco-regional disease recurrence (P = 0.036). Using a cut-off level of 400 pg/mL, a low level of sANG predicted tumour recurrence with a relative risk of 4.0 (95% CI: 0.7-24.0). Plasma endostatin was associated with higher histological grade (P = 0.01) and with both disease recurrence (P = 0.045) and death from disease (P = 0.021). Plasma endostatin above a cut-off point of 70 ng/mL could predict tumour recurrence with a relative risk of 4.7 (95% CI: 1.1-19.7). These data suggest that plasma endostatin and sANG have potential roles as prognostic factors and require further investigation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11903369     DOI: 10.1046/j.0307-7772.2001.00519.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  12 in total

1.  Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells.

Authors:  Shunsuke Fukumoto; Masayo Morifuji; Yoshinori Katakura; Masamichi Ohishi; Seiji Nakamura
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Clinical significance of serum and tumor tissue endostatin evaluation in operable non-small cell lung cancer.

Authors:  Ming-Ming Hu; Ying Hu; Hai-Qing Zhang; Wen-Yun Jia; Zhe Qian; Yuan Yang; Bao-Lan Li
Journal:  Biomed Rep       Date:  2014-07-25

Review 3.  Angiogenin-mediated ribosomal RNA transcription as a molecular target for treatment of head and neck squamous cell carcinoma.

Authors:  Lili Chen; Guo-fu Hu
Journal:  Oral Oncol       Date:  2010-07-24       Impact factor: 5.337

4.  Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites.

Authors:  Daye Cheng; Bin Liang; Hong Kong
Journal:  Med Oncol       Date:  2011-05-10       Impact factor: 3.064

5.  Increased serum levels of endostatin in patients with idiopathic pulmonary fibrosis.

Authors:  Masaaki Sumi; Hiroaki Satoh; Katsunori Kagohashi; Hiroichi Ishikawa; Kiyohisa Sekizawa
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

6.  Association of Oral Cavity and Oropharyngeal Cancer Biomarkers in Surgical Drain Fluid With Patient Outcomes.

Authors:  Amy Anne D Lassig; Anne M Joseph; Bruce R Lindgren; Bevan Yueh
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-07-01       Impact factor: 6.223

7.  Serum angiogenin levels predict treatment response in patients with stage IV melanoma.

Authors:  Pia Vihinen; Minna Kallioinen; Meri-Sisko Vuoristo; Johanna Ivaska; Kari J Syrjänen; Marjo Hahka-Kemppinen; Pirkko-Liisa Kellokumpu-Lehtinen; Seppo O Pyrhönen
Journal:  Clin Exp Metastasis       Date:  2007-08-29       Impact factor: 5.150

8.  Endostatin levels in exudative pleural effusions.

Authors:  M Sumi; K Kagohashi; H Satoh; H Ishikawa; Y Funayama; K Sekizawa
Journal:  Lung       Date:  2003 Nov-Dec       Impact factor: 2.584

9.  Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix.

Authors:  Chandra Shekhar Boosani; Yakkanti A Sudhakar
Journal:  Pharmaceuticals (Basel)       Date:  2011-12

Review 10.  Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma.

Authors:  Suvi-Tuuli Vilen; Tuula Salo; Timo Sorsa; Pia Nyberg
Journal:  ScientificWorldJournal       Date:  2013-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.